Direct answer: The FDA published the draft " Electronic Submission Template for Premarket Approval Applications (PMA) " in September 2026 to introduce PMA and part of PMA supplementary applications to CDRH and CBER to the public resources available and PMA eSTAR content. It is currently a non-binding draft and may still be modified; As at the date of reconciliation, the FDA page did not show that it had been finalized; the nature of the document, the current status and the enterprise recommendations are set out below; Specific products should be judged in the official language.
What is this file, at what stage?
The regulatory document and its status referred to in this paper is based on the original FDA page listing. The document is for comments only; The template description is not equivalent to the new substantive review criteria.
A distinction should be made between binding regulations/final rules and FDA guides, drafts, discussion papers or enforcement policies. The latter have different legal effects; Specific sources of restraint are governed by the documents and by the legislation cited.
Which enterprises and products need attention?
Enterprises preparing PMA or applying PMA supplementary applications and their declaration teams.
It is recommended that this be confirmed on a product-business role-US market-based basis; Where product classifications or responsible subjects cannot be judged by name alone, the labels are subject to individual checks.
Where is the change from what was previously requested?
The substance of the document and the background to the previous rules are set out below. Only changes specified in official documents are considered to be changes; The recommendatory content is not to be added to the mandatory obligation.
Direct answer:The FDA published the draft " Electronic Submission Template for Premarket Approval Applications (PMA) " in September 2026 to introduce PMA and part of PMA supplementary applications to CDRH and CBER to the public resources available and PMA eSTAR content. It is currently a non-binding draft and may still be modified; As at the date of reconciliation, the FDA page did not show that it had been finalized.
The draft describes the structure and organizational direction of the information in the current PMA eSTAR template and covers the type of submission, applicant and contact person, forward communication, products and supporting information. The objective was to assist the author in preparing a structured electronic application; The draft text itself did not represent a new set of mandatory requirements that had entered into force.
- Confirm whether products require PMA and whether the application is under the responsibility of CDRH or CBER.
- View the applicable PMA legislation, final guide, current eSTAR version and FDA Portal requirements.
- Collating applicants, authorized representatives, product descriptions, clinical and non-clinical evidence and past communication information.
- Checks current official template versions, file formats and cost requirements prior to submission.
- Changes in the duration and version of comments on the draft are based on the FDA guide page and the Federal Register notification.
Key dates and transitional arrangements
The following dates are derived from the factual summary of the documents retained here. A distinction should be made between the date of issuance, the date of closure of comments and the date of entry into force/application of the respective documents. There is no presumption in respect of matters that are not clearly stated in the original text.
- September 2026: Date of issuance of the document (as expressed in the original language of the adjacent official).
The date of publication/update of the website’s articles does not correspond to the date of implementation of the statute; If the dates of the official pages differ, reference is made to the official document and the current FDA page.
How can Chinese companies prepare?
- The type of submission and the applicability of the eSTAR are confirmed before administrative information, product information, non-clinical/clinical evidence and cross-references are organized according to templates.
- Identify those responsible, sources and internal review nodes, and maintain official page versions and verification dates.
- If the official document is revised, withdrawn or the final version issued, the applicable conclusions are reassessed and the records updated.
For this purpose, the recommendation does not substitute for the obligation set out in the body of the statute.
Exceptions, pending confirmations and common misreading
- The document is for comments only; The template description is not equivalent to the new substantive review criteria.
- When exemptions, transition periods, border products or different business actors are encountered, the original text should be consulted on the basis of specific facts; Uncertainties should be clearly identified for confirmation.
- Registration, listing, submission or obtaining of a reply should not be mistakenly referred to as FDA approval or authentication.
Official information and reconciliation records
- FDA:PMA Electronic Submission Template(Draft Guidance,2026-09)
- FDA: PMA eSTAR Draft Document
- FDA:eSTAR Program
(b) The station’s author: Mr. Toshito. Reviewer: Mr. Toto. Date of the structural review of the article: 2026-11-02; The statutory status and specific obligations are based on the official language listed.
Next
Identification of scope of application by product and corporate role, viewing Regulatory UpdatesAnd the corresponding FDA Compliance Service Scope; If you need a case judgement, you can do it. Contact PageSubmission of product information.